Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

NCT00850382 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

89

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Dasatinib
DRUG: daunorubicin
DRUG: Cytarabine

Sponsor

University of Ulm